Eight patients with severe congestive heart failure refractory to conventional therapy, including vasodilators, were given captopril (seven patients) or teprotide (one patient). All had dyspnea, edema, elevated pulmonary wedge pressure (28.0 +/- 2.6 mm Hg), low cardiac index (1.6 +/- 0.1 liters per minute per square meter), and elevated levels of serum creatinine (2.3 +/- 0.2 mg per deciliter [203.3 +/- 17.7 mumol per liter]), blood urea nitrogen (48 +/- 5 mg per deciliter [17.1 +/- 1.8 mmol of urea per liter]), plasma renin activity (21 +/- 7 ng of angiotensin I per milliliter per hour), plasma angiotensin II (271 +/- 51 pg per milliliter), and plasma aldosterone (65 +/- 14 ng per deciliter). After one week of therapy, all indexes improved. Creatinine and p-aminohippurate clearances were also increased (P less than 0.01). Improvement was sustained (more than six months) and was associated with a statistically significant increase in the cardiac ejection fraction (12 +/- 3 to 26 +/- 7 per cent). With a mean follow-up of seven months, the New York Heart Association Functional Class has been reduced from IV to II, and the number of days of hospitalization to less than 10 per cent of that before captopril therapy. We conclude that captopril reduces afterload in advanced congestive heart failure and induces sustained improvements in clinical status and renal function.
This article has been cited by other articles:
Fisher, N. D.L., Jan Danser, A.H., Nussberger, J., Dole, W. P., Hollenberg, N. K.
(2008). Renal and Hormonal Responses to Direct Renin Inhibition With Aliskiren in Healthy Humans. Circulation
117: 3199-3205
[Abstract][Full Text]
Pfeffer, M. A., Frohlich, E. D.
(2006). Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation. Am. J. Physiol. Heart Circ. Physiol.
291: H2021-H2025
[Abstract][Full Text]
Ryckwaert, F., Colson, P., Ribstein, J., Boccara, G., Guillon, G.
(2001). Haemodynamic and renal effects of intravenous enalaprilat during coronary artery bypass graft surgery in patients with ischaemic heart dysfunction{{dagger}}. Br J Anaesth
86: 169-175
[Abstract][Full Text]
Colson, P., Ryckwaert, F., Coriat, P.
(1999). Renin Angiotensin System Antagonists and Anesthesia. Anesth. Analg.
89: 1143-1143
[Full Text]
Ma, R., Schultz, H. D., Wang, W.
(1999). Chronic central infusion of ANG II potentiates cardiac sympathetic afferent reflex in dogs. Am. J. Physiol. Heart Circ. Physiol.
277: H15-H22
[Abstract][Full Text]
Brown, N. J., Vaughan, D. E.
(1998). Angiotensin-Converting Enzyme Inhibitors. Circulation
97: 1411-1420
[Abstract][Full Text]
Hollenberg, N. K., Guidi, E.
(1998). ACE Inhibitors and Renal Vascular Responses in the Spontaneously Hypertensive Rat. J CARDIOVASC PHARMACOL THER
3: 161-169
[Abstract]
Ma, R., Zucker, I. H., Wang, W.
(1997). Central gain of the cardiac sympathetic afferent reflex in dogs with heart failure. Am. J. Physiol. Heart Circ. Physiol.
273: H2664-H2671
[Abstract][Full Text]
Annane, D., Bellissant, E., Pussard, E., Asmar, R., Lacombe, F., Lanata, E., Madonna, O., Safar, M., Giudicelli, J.-F., Gajdos, P.
(1996). Placebo-Controlled, Randomized, Double-Blind Study of Intravenous Enalaprilat Efficacy and Safety in Acute Cardiogenic Pulmonary Edema. Circulation
94: 1316-1324
[Abstract][Full Text]
Munger, M. A., Gardner, S. F., Jarvis, R. C.
(1990). Endocrinologic Warfare: The Role of Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure. Journal of Pharmacy Practice
3: 318-331
[Abstract]
Koning, H.M.
(1989). Review article : Renal function and open-heart surgery. Perfusion
4: 1-8
